ASH Compendium of Presentations

1 ASH 2021 VIRTUAL SCIENTIFIC PROGRAMDECEMBER 11 14, 2021 Bristol Myers SquibbCompendium of presentationsThis booklet may represent investigational, unapproved uses of some products listed. The safety and efficacy of investigational agents and/or investigational uses or combinations of agents approved for other indications have not been established. There is no guarantee that investigational agents or regimens will receive health authority approval or become commercially available in any country for the uses being investigated. This compilation of Presentations is intended as an educational resource and is for the exchange of scientific data with clinical investigators and healthcare on date to see a list of scheduled Presentations ; click on a therapeutic area to go directly to those of ContentsSaturday, December 11 multiple myeloma Lymphoma Leukemia Thalassemia Myelofibrosis Myelodysplastic Syndromes Other Sunday, December 12 multiple myeloma Lymphoma Leukemia Thalassemia Myelofibrosis Monday, December 13 Lymphoma Leukemia Thalassemia Myelofibrosis Myelodysplastic Syndromes Other 3 Saturday, December 11 multiple MYELOMAOral PresentationsPresentation #117: Real-world treatment patterns and clinical, economic, and humanistic burden in triple class refractory multiple myeloma : analysis of the CONNECT multiple myeloma (MM) disease registryLead Author and Presenter: Derek Tang, Sundar Jagannath*.

2 Bristol Myers Squibb, Princeton, NJ, USAS ession: Outcomes research lymphoid malignancies: multiple myeloma and other plasma cell disordersPresentation #162: Iberdomide (IBER) in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from the dose-expansion phase of the CC-220-MM-001 trialLead Author and Presenter: Sagar Lonial, Emory University, Atlanta, GA, USAS ession: myeloma and plasma cell dyscrasias: clinical-prospective therapeutic trials: novel targets and amyloidPoster PresentationsPresentation #1613: Pre-clinical and clinical immunomodulatory effects of pomalidomide or CC-92480 in combination with bortezomib in multiple myelomaLead Author and Presenter: Chad Bjorklund, Bristol Myers Squibb, Princeton, NJ, USAS ession: multiple myeloma and plasma cell dyscrasias: basic and translational: poster IPresentation #1662: Impact of elotuzumab plus pomalidomide/dexamethasone on health-related quality of life for patients with relapsed/refractory multiple myeloma (RRMM): final data from the phase 2 ELOQUENT-3 trialLead Author and Presenter: Katja Weisel, University Medical Center of Hamburg-Eppendorf, Hamburg, GermanySession: myeloma and plasma cell dyscrasias: clinical-prospective therapeutic trials: poster IPresentation #1739: Baseline correlates of complete response to idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy in patients with relapsed and refractory multiple myeloma : subanalysis of the KarMMa trialLead Author and Presenter.

3 Nina Shah, University of California San Francisco, San Francisco, CA, USAS ession: Cellular immunotherapies: clinical: poster I*Presenter differs from lead author4 Poster PresentationsPresentation #1978: Matching-adjusted indirect comparisons of efficacy outcomes in patients with relapsed and refractory multiple myeloma for idecabtagene vicleucel (KarMMa) versus selinexor plus dexamethasone (STORM part 2) and belantamab mafodontin (DREAMM-2): updated analysis with longer follow-up Lead Author and Presenter: Paula Rodriguez-Otero, Cl nica Universidad de Navarra, Pamplona, SpainSession: Outcomes research lymphoid malignancies: poster I LYMPHOMAOral PresentationPresentation #91: Lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, versus standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): results from the randomized phase 3 TRANSFORM study Lead Author and Presenter: Manali Kamdar, University of Colorado Cancer Center, Denver, CO, USAS ession: Cellular immunotherapies: cellular therapies for lymphomasAccepted for ASH Annual Meeting Press ProgramPoster PresentationsPresentation #1200: CC-99282 is a novel cereblon (CRBN) E3 ligase modulator (CELMoD) agent with enhanced tumoricidal activity in preclinical models of lymphomaLead Author and Presenter.

4 Soraya Carrancio, Bristol Myers Squibb, Princeton, NJ, USAS ession: Molecular pharmacology and drug resistance: lymphoid neoplasms: poster IPresentation #1460: CONNECT lymphoma disease registry: a US-based, prospective, observational cohort studyLead Author and Presenter: Christopher Flowers, The University of Texas MD Anderson Cancer Center, Houston, TX, USAS ession: Aggressive lymphomas: clinical and epidemiological: poster IPresentation #1762: Outreach: results from a phase 2 study of lisocabtagene maraleucel (liso-cel) administered as inpatient (Inpt) or outpatient (Outpt) treatment in the nonuniversity setting in patients (pts) with R/R large B-cell lymphoma (LBCL)Lead Author and Presenter: John Godwin, Earle A. Chiles Research Institute, Portland, OR, USAS ession: Cellular immunotherapies: clinical: poster I5 LEUKEMIAOral PresentationsPresentation #277: Real-world evidence comparing venetoclax plus azacitidine (VEN-AZA) vs.

5 Intensive chemotherapy (IC) as induction for patients with acute myeloid leukemia (AML): retrospective analysis of an electronic medical records database in the United StatesLead Author and Presenter: Amer Zeidan, Yale University, New Haven, CT, USAS ession: Outcomes research myeloid malignancies: real world outcomes Presentation #279: treatment patterns and survival outcomes of patients with acute myeloid leukemia who achieved remission in the CONNECT myeloid disease registryLead Author and Presenter: Gail Roboz, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY, USAS ession: Outcomes research myeloid malignancies: real world outcomes Poster PresentationsPresentation #1243: Outcomes for patients with late-stage mutant-IDH2 (mIDH2) relapsed/refractory acute myeloid leukemia (R/R AML) treated with enasidenib vs other lower-intensity therapies in the randomized, phase 3 IDHentify trialLead Author and Presenter: Courtney DiNardo, The University of Texas MD Anderson Cancer Center, Houston, TX, USAS ession: Acute myeloid leukemias: commercially available therapies, excluding transplantation and cellular immunotherapies: poster IPresentation #1244: Health-related quality of life (HRQoL) during treatment with enasidenib (ENA) plus azacitidine (AZA) in patients with newly diagnosed mutant IDH2 (mIDH2) acute myeloid leukemia (AML) not eligible for intensive chemotherapy (IC)Lead Author and Presenter.

6 Courtney DiNardo, The University of Texas MD Anderson Cancer Center, Houston, TX, USAS ession: Acute myeloid leukemias: commercially available therapies, excluding transplantation and cellular immunotherapies: poster I6 THALASSEMIAP oster PresentationPresentation #1955: Systematic literature review of the indirect costs, humanistic burden, patient or caregiver preference, and qualitative outcomes in beta-thalassemiaLead Author and Presenter: Yesim Aydinok, Ege University, Izmir, TurkeySession: Outcomes research non-malignant conditions: poster IMYELOFIBROSISP oster PresentationsPresentation #1490: A phase 3 study of efficacy and safety of luspatercept versus placebo in patients with myeloproliferative neoplasm-associated myelofibrosis on JAK2 inhibitor therapy and requiring red blood cell transfusionsLead Author and Presenter: Ruben Mesa, UT Health San Antonio Cancer Center, San Antonio, TX, USAS ession: Myeloproliferative syndromes: clinical and epidemiological: poster IPresentation #1980: Clinical outcomes at 3 and 6 months of fedratinib therapy following prior ruxolitinib failure: real-world assessment of spleen, symptoms, and hematologic responseLead Author and Presenter: John Mascarenhas, Icahn School of Medicine at Mount Sinai, New York, NY, USAS ession: Outcomes research myeloid malignancies: poster IMYELODYSPLASTIC SYNDROMESP oster PresentationPresentation #1524.

7 Analysis of duration of response, exposure-adjusted safety and progression to acute myeloid leukemia (AML) for patients with lower-risk myelodysplastic syndromes (LR-MDS) receiving luspatercept in the MEDALIST studyLead Author and Presenter: Uwe Platzbecker, University Hospital Leipzig, Leipzig, GermanySession: Myelodysplastic syndromes clinical and epidemiological: poster I7*Presenter differs from lead authorOTHERP oster PresentationPresentation #1951: Discordance between treatment guideline recommendations and real-world practice in a group of large integrated delivery networks for venous thromboembolism (VTE) patients: a closer look at VTE patients with cancerLead Author and Presenter: Juzer Lotya, Amol Dhamane*; IQVIA Inc., Dublin, Ireland and Bristol Myers Squibb, Princeton, NJ, USAS ession: Outcomes research non-malignant conditions: poster I Sunday, December 12 multiple MYELOMAOral PresentationPresentation #548: Updated clinical and correlative results from the phase I CRB-402 study of the BCMA-targeted CAR-T cell therapy bb21217 in patients with relapsed and refractory multiple myelomaLead Author and Presenter: Noopur Raje, Massachusetts General Hospital, Boston, MA, USAS ession: Cellular immunotherapies: cellular therapies for myelomaPoster PresentationsPresentation #2658: Super-enhancer driven regulation of CKS1B in multiple myeloma : implications in mediating response to BET inhibitor and CELMoD agent combinationLead Author and Presenter: Aarif Ahsan, Bristol Myers Squibb, Princeton, NJ, USAS ession.

8 multiple myeloma and plasma cell dyscrasias: basic and translational: poster II Presentation #2669: CC-92480 enhances cell-autonomous cytotoxicity through blockade of G2/M transition when combined with bortezomib/dexamethasone in pre-clinical multiple myelomaLead Author and Presenter: Chad Bjorklund, Bristol Myers Squibb, Princeton, NJ, USAS ession: multiple myeloma and plasma cell dyscrasias: basic and translational: poster II8 Poster PresentationsPresentation #2681: Location of the t(4;14) translocation breakpoint identifies a subset of newly-diagnosed multiple myeloma patients with poor prognosis Lead Author and Presenter: Nicholas Stong, Bristol Myers Squibb, Princeton, NJ, USAS ession: multiple myeloma and plasma cell dyscrasias: basic and translational: poster II Presentation #2731: CC-92480, a potent, novel cereblon E3 ligase modulator (CELMoD) agent, in combination with dexamethasone (DEX) and bortezomib (BORT) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): preliminary results from the phase 1/2 study CC-92480-MM-002 Lead Author and Presenter: Paul Richardson, Dana-Farber Cancer Institute, Boston, MA, USAS ession: myeloma and plasma cell dyscrasias: clinical-prospective therapeutic trials: poster IIPresentation #2743.

9 Subsequent anti- myeloma therapy after idecabtagene vicleucel (Ide-cel, bb2121) treatment in patients with relapsed/refractory multiple myeloma from the KarMMa studyLead Author and Presenter: Paula Rodriguez-Otero, Cl nica Universidad de Navarra, Pamplona, SpainSession: myeloma and plasma cell dyscrasias: clinical-prospective therapeutic trials: poster IIPresentation #2835: Updated health-related quality of life results from the KarMMa clinical study in patients with relapsed and refractory multiple myeloma treated with the B-cell maturation antigen-directed chimeric antigen receptor T cell therapy idecabtagene vicleucel (ide-cel, bb2121)Lead Author and Presenter: Michel Delforge, University Hospital Leuven, Leuven, BelgiumSession: Cellular immunotherapies: clinical: poster IIPresentation #3041: Idecabtagene vicleucel (ide-cel, bb2121), a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy: qualitative analyses of post- treatment interviews (months 6 24) for patients with relapsed and refractory multiple myeloma in the KarMMa clinical trialLead Author and Presenter: Nina Shah, University of California San Francisco, San Francisco, CA, USAS ession: Outcomes research lymphoid malignancies: poster II 9 LYMPHOMAP oster PresentationsPresentation #2271: Discover